News Information
Focusing on cutting-edge technology and conveying industry voices
The Future of Biopharma is Cell-Free: Partner with PLD Technology to Lead the Frontier
The winds of change are here, and the science-and-tech sector is ripe with opportunity. PLD Technology is a global pioneer in Cell-Free Protein Synthesis (CFPS) technology. By leveraging groundbreaking foundational innovations, we are disrupting industry barriers and capturing market leadership with premium, high-performance products.
2026/04/23
Traditional antibody discovery resembles a marathon: construction, transfection, expression, purification, and screening—processes that can span weeks or even months, with limited throughput and low success rates for difficult-to-express antibodies or toxic proteins. Moreover, many potentially highly active antibodies are mistakenly classified as “negative” due to insufficient expression levels, resulting in the loss of promising candidates. In contrast, cell-free protein synthesis (CFPS) technology creates an “ultra‑fast pathway” for antibody screening, compressing workflows that traditionally take weeks or months down to just days. Drawing on existing literature, CFPS has demonstrated two key advantages in antibody screening:
2026/04/14
The disconnect between computational modeling and experimental performance has long been a core challenge in the field of protein engineering that urgently requires breakthroughs. In this study, we introduce ORI (Ontology Reinforcement Iteration), a scalable, general-purpose computational framework for functional protein engineering. This framework seamlessly integrates ontology‑condition decoding with reinforcement learning informed by wet‑lab feedback (RLWF), thereby establishing a fully closed‑loop iterative optimization pipeline.
2026/03/25
From March 31 to April 1, 2026, the Fifth China Synthetic Biology and Biomanufacturing Conference will be held at the Hangzhou Heda DoubleTree by Hilton Hotel. This conference will feature Dr. Cui Jinhui, CEO of Suzhou Perotin Biotechnology Co., Ltd., who will deliver a keynote presentation titled “A Cell-Free Protein Expression Platform: Empowering Efficient Front-End R&D in Biomanufacturing Processes.” As a leading company in cell-free protein expression technology, Perotin Biotechnology will also exhibit at the Fifth China Synthetic Biology and Biomanufacturing Conference (Booth No. A10). We warmly invite both new and existing customers to visit our booth.
2026/03/19
Highlights | The Perotin Yimao Trade Fair Concludes Successfully!
On March 14, 2026, the 11th Yimao Bio‑Industry Exhibition (BIOCHINA 2026) successfully concluded at the Suzhou International Expo Center. As the annual highlight of the biopharmaceutical sector, this year’s event was themed “Integration & Leadership,” bringing together over 30,000 industry professionals from more than 40 countries and regions to discuss the latest trends and future directions of the biopharmaceutical industry. PLD Technology was invited to participate in interviews and showcased its products with great distinction, presenting its core cell‑free protein expression solutions and fully demonstrating its innovative strength at this premier industry gathering, reaping abundant recognition and opportunities.
2026/03/19
In the fields of metabolic engineering and synthetic biology, research efficiency has long been constrained by a persistent challenge: while design capabilities continue to improve, the pace of experimental validation consistently lags behind. With advances in computational design, automation, and AI technologies, researchers can now generate vast numbers of enzyme‑mutant and metabolic‑pathway design options in a short time. However, how to rapidly screen and validate these designs remains a critical bottleneck that limits progress in R&D.
2026/03/18
In recent years, the influence of machine learning (ML) in the field of protein science has expanded rapidly. From the structural‑prediction revolution sparked by AlphaFold to various sequence‑generation models used for protein design, algorithms are exploring the protein sequence space at an unprecedented pace. However, a persistent challenge remains: while algorithms can “generate hypotheses,” the quality and functionality of proteins still require validation through experimental data. Particularly in enzyme engineering and functional protein optimization, ML models place increasingly stringent demands on training datasets—requiring not only large volumes but also accurate representations of functional diversity. Traditional workflows that rely on cellular expression, purification, and kinetic characterization are often time‑consuming and limited in throughput, frequently becoming bottlenecks in the iterative cycle of ML development. Against this backdrop, a study published by Thornton et al. in ACS Synthetic Biology offers a highly representative approach to addressing these challenges:
2026/03/06
GLP1R (Glucagon-like peptide-1 receptor), known in Chinese as the “glucagon-like peptide‑1 receptor,” is a G protein–coupled receptor (GPCR). This receptor is predominantly expressed in pancreatic β cells, the gastrointestinal tract, and the brain, with particularly critical expression in pancreatic β cells. Functionally, GLP1R serves as the specific receptor for glucagon-like peptide‑1 (GLP‑1). When GLP‑1—a gut‑derived incretin secreted by intestinal L cells—binds to GLP1R, it activates downstream signaling pathways, such as the cAMP/PKA pathway, thereby promoting insulin synthesis and secretion, inhibiting glucagon release, and delaying gastric emptying. Moreover, GLP‑1 signaling enhances the proliferation of pancreatic β cells while suppressing their apoptosis, thus playing a central role in maintaining glucose homeostasis.
2026/02/24
Contact Information
Service Hotline: +86-512-67900128
Customer Service: order@sz-pld.tech
Business Cooperation: bd@sz-pld.tech
Address: Room 302, Building 1, Weili Medical Science and Technology Park, No. 69 Jiepu Road, Suzhou Industrial Park
